Beddow Capital Management Inc. boosted its position in Organon & Co. (NYSE:OGN - Free Report) by 41.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 432,300 shares of the company's stock after purchasing an additional 125,625 shares during the period. Organon & Co. comprises 2.7% of Beddow Capital Management Inc.'s investment portfolio, making the stock its 15th biggest position. Beddow Capital Management Inc. owned approximately 0.17% of Organon & Co. worth $6,450,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the company. Prospera Private Wealth LLC acquired a new stake in Organon & Co. during the 3rd quarter valued at $25,000. Horizon Bancorp Inc. IN lifted its position in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock valued at $25,000 after acquiring an additional 1,585 shares in the last quarter. Millstone Evans Group LLC acquired a new stake in shares of Organon & Co. during the fourth quarter valued at $29,000. Larson Financial Group LLC increased its position in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after purchasing an additional 1,734 shares in the last quarter. Finally, Riverview Trust Co increased its position in Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after purchasing an additional 1,292 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.
Organon & Co. Trading Down 0.1 %
NYSE:OGN traded down $0.02 during trading hours on Wednesday, reaching $14.71. 3,151,453 shares of the company were exchanged, compared to its average volume of 2,418,913. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of 4.42, a PEG ratio of 0.90 and a beta of 0.76. The stock has a 50 day simple moving average of $15.41 and a 200 day simple moving average of $16.33. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. As a group, analysts predict that Organon & Co. will post 3.68 EPS for the current year.
Organon & Co. Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.62%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s payout ratio is currently 33.63%.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on OGN. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Morgan Stanley reduced their price target on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. Finally, Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Organon & Co. presently has an average rating of "Hold" and a consensus price target of $20.80.
Check Out Our Latest Analysis on Organon & Co.
About Organon & Co.
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Featured Stories
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
